Manufacturing a spinal regenerative medicine in the East Midlands

在东米德兰兹制造脊柱再生药物

• 批准号: 77588
• 金额: $ 10.46万
• 依托单位: LOCATE BIO LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=77588
• 关键词: Manufacturing; spinal; regenerative; medicine; East

The UK has invested for many years in the science of regenerative medicine. This field is delivering on its promise to repair human tissues. Given the UK's strong position in the science that underpins this area we should also aim to develop a world-leading industry that exports regenerative medicines across the world. This project aims to demonstrate that the UK can lead in the manufacture of one class of these medicines, called regenerative matrices. These products are materials that are used by surgeons to regenerative tissue after implantation in patients. The manufacturing of these products shares some processes with those used for the pharmaceutical industry but there is a need for innovation.Locate Bio is focusing on developing regenerative matrices for the treatment of patients with lower back pain (LBP). LBP is the leading cause of disability in the UK and most countries in the world. A major cause of LBP is disc degenerative disease where the shock absorber made of cartilage between the bony vertebrae of the spine lose their structure. The surgical treatment of disc degenerative disease is very expensive and patients can encounter long-term side-effects. Locate Bio's first product lowers the cost and risk of these treatments.Most of the expertise for manufacturing of these products lies outside of the UK. Under this SMART Award, Locate Bio will develop the manufacturing processes for regenerative matrices to lay the foundations for product launches in China, USA, UK and the EU.

英国多年来一直在再生医学科学方面进行投资。这一领域正在兑现其修复人体组织的承诺。鉴于英国在支撑这一领域的科学方面的强大地位，我们还应该致力于发展一个世界领先的产业，在世界各地出口再生药物。该项目旨在证明英国可以在制造一类称为再生基质的药物方面处于领先地位。这些产品是外科医生在植入患者体内后用于再生组织的材料。这些产品的生产过程与制药行业的生产过程相同，但需要创新。Locate Bio专注于开发用于治疗下背痛（LBP）患者的再生基质。LBP是英国和世界上大多数国家残疾的主要原因。腰痛的主要原因是椎间盘退行性疾病，其中由脊椎骨椎骨之间的软骨制成的减震器失去了它们的结构。椎间盘退行性疾病的手术治疗非常昂贵，患者可能会遇到长期的副作用。Locate Bio的第一个产品降低了这些治疗的成本和风险。这些产品的大部分制造技术都在英国之外。根据这项SMART奖项，Locate Bio将开发再生基质的制造工艺，为在中国，美国，英国和欧盟推出产品奠定基础。